Kenvue Inc. $KVUE Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 37.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 142,047 shares of the company’s stock after selling 83,261 shares during the quarter. Intech Investment Management LLC’s holdings in Kenvue were worth $3,406,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of KVUE. Starboard Value LP purchased a new position in Kenvue in the 4th quarter worth about $467,864,000. Vanguard Group Inc. boosted its holdings in shares of Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock worth $5,494,882,000 after buying an additional 10,600,682 shares during the period. Third Point LLC purchased a new position in shares of Kenvue in the first quarter worth approximately $213,422,000. Maverick Capital Ltd. acquired a new stake in shares of Kenvue during the first quarter valued at approximately $203,036,000. Finally, Nuveen LLC purchased a new stake in shares of Kenvue in the 1st quarter valued at approximately $187,123,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.9%

KVUE opened at $19.03 on Friday. The company has a market capitalization of $36.52 billion, a PE ratio of 25.71, a price-to-earnings-growth ratio of 2.71 and a beta of 0.83. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. Kenvue Inc. has a fifty-two week low of $17.15 and a fifty-two week high of $25.17. The business has a 50-day moving average of $21.14 and a 200-day moving average of $22.23.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.28 by $0.01. The business had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is 112.16%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on KVUE shares. Canaccord Genuity Group lowered their price objective on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Citigroup lowered their price target on Kenvue from $24.50 to $22.00 and set a “neutral” rating on the stock in a report on Tuesday, July 15th. JPMorgan Chase & Co. reduced their price objective on Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, July 25th. Bank of America lowered their target price on Kenvue from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, July 15th. Finally, Barclays dropped their target price on Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a report on Tuesday, July 15th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $24.21.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.